Business Daily Media

Business Marketing

.

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

  • Written by ACN Newswire - Press Releases

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

TOKYO, Sep 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant];

Read more //?#

Popular

Calls for mental health reform in the workplace sparked by record-breaking calls to suicide hotline

Amid fears that mental health repercussions of COVID-19 will outlast the physical impacts, organisational psychologists are urging Australian business leaders to tackle the issue of mental health not just at home but at the ...

APR Pty Ltd Raises $5 Million To Fund Expanding Everlast Branded Products

Australian Product Research Pty Ltd Raises $5 Million To Fund Expanding Everlast Branded Products in Australian Market Australian Product Research Pty Ltd (“APR” or “Company”), a fast growing beverage company is pleased to anno...

Navigating Offshoring Success: A Strategic Guide to Maximising Benefits

In today's dynamic business landscape, offshoring has become a pivotal strategy for companies aiming to enhance efficiency, access global talent, and drive growth. As a seasoned expert with over a decade of firsthand experienc...